(PRWEB) August 30, 2013
A group of plaintiffs have filed a GranuFlo lawsuit in California state court, alleging that drug maker Fresenius sold dialysis drug GranuFlo while failing to inform the public of the serious potential risks of use of the drug, including heart attack and stroke, according to court documents. The Rottenstein Law Group LLP, which represents clients in GranuFlo dialysis injury lawsuits, maintains a web page that features information on GranuFlo side effects and lawsuits.
In June 2012 the U.S. Food and Drug Administration issued a Class 1 Recall after learning about the alleged adverse side effects involving the heart.* The FDA had originally approved the drug for distribution in 2003. The plaintiffs argue in the lawsuit that Fresenius warned its doctors at its own dialysis centers about the health risks of GranuFlo, but it did not warn anyone outside the organization (Rodriguez et al. v. Fresenius USA Inc. et al.; BC519374, Los Angeles Superior Court, California). According to court documents, the FDA received a copy of the memo in March 2012 and subsequently took action.
“If these very serious allegations are true, then the courts should hold this company accountable,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “The plaintiffs—and our own clients on whose behalf we file GranuFlo lawsuits—put their lives in the hands of this company and deserve justice.”
The Rottenstein Law Group LLP encourages those who believe they have suffered from the alleged side effects of GranuFlo to download a free informational brochure about the drug to learn more about its side effects and how to file a lawsuit.
Copyright©2012 Vocus, Inc.
All rights reserved